- Oops!Something went wrong.Please try again later.
Dermapharm Holding SE / Key word(s): Change in Forecast
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
Dermapharm Holding SE raises EBITDA forecast for the full year 2021
Grünwald, December 16, 2021 - The Management Board of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) analysed the business development in November on the basis of the preliminary figures in its Management Board meeting today and decided to adjust the forecast for the financial year 2021. Accordingly, the Executive Board now expects Group EBITDA1 to grow by 70 to 75 percent compared to the previous year (previously: 50 to 60 percent). In addition, the Executive Board confirms the revenue forecast for the 2021 financial year of 15 to 20 percent growth compared to the same period of the previous year.
1 EBITDA is an alternative performance indicator that is not defined according to international accounting standards. The Company uses these metrics to allow for better comparability of the business over time and within the industry. EBITDA is defined as earnings before interest, taxes, depreciation and amortisation (see Dermapharm page 31, Annual Report 2020).
>End of the Ad hoc announcement<
Investor Relations & Corporate Communications
16-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Dermapharm Holding SE
+49 (0)89 64 86-0
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID:
End of Announcement
DGAP News Service